Tamoxifen for early breast cancer: An overview of the randomised trials

The Lancet

Volumn 351, Issue 9114, 1998, Pages 1451-1467

  Abe, O ^a   Abe, R ^a   Enomoto, K ^a   Kikuchi, K ^a   Koyama, H ^a   Nomura, Y ^a,bi   Sakai, K ^a   Sugimachi, K ^a   Tominaga, T ^a   Uchino, J ^a   Yoshida, M ^a   van de Velde, A O ^b   van Dongen, J A ^b   Vermorken, J B ^b   Giokas, G ^c   Lissaios, B ^c   Harvey, V J ^d   Holdaway, T M ^d   Kay, R G ^d   Mason, B H ^d   Coates, A ^e   Forbes, J F ^e   Focan, C ^f   Lobelle, J P ^f   Peek, U ^g   Oates, G D ^h   Powell, J ^h   Durand, M ⁱ   Mauriac, L ⁱ   Bartholomeus, S ^j   Piccart, M J ^j   Gelman, R S ^k   Harris, J R ^k   Shapiro, C L ^k   Hancock, A K ^l   Masood, M B ^l   Parker, D ^l   Price, J J ^l   Jackson, S ^m   Ragaz, J ^m   Delozier, T ⁿ   Mace Lesec'h J ⁿ   Haybittle, J L ^o   Cirrincione, C ^p   Henderson, I C ^p   Korzun, A ^p   Weiss, R B ^p   Wood, W C ^p   Baum, M ^q,bx   Houghton, J ^q   Riley, D ^q   Dent, D M ^r   Gudgeon, C A ^r   Hacking, A ^r,db   Horgan, K ^s   Hughes, L ^s   Stewart, H J ^s,de   Gordon, N H ^t   Davis, H L ^u   Romestaing, P ^v   Lehingue, Y ^v   Owen, J R ^w   Meier, P ^x   Howell, A ^y   Ribeiro, G G ^y   Swindell, R ^y,ca   Albano, J ^z   de Oliveira, C F ^z   Gervasio H ^z   Gordilho, J ^z   Carstensen, B ^aa   Palshof, T ^aa   Johansen, H ^ab   Korzeniowski, S ^ac   Skolyszewski, J ^ac   Portnoj, S M ^ad   Andersen, K W ^ae   Axelsson, C K ^ae   Blichert Toft, M ^ae   Mouridsen, H T ^ae   Overgaard, M ^ae   Rose, C ^ae   Corcoran, N ^af   Trampisch, H J ^ag   Comis, R L ^ah   Davidson, N E ^ah   Gray, R ^ah,cm   Robert, N ^ah   Tormey, D C ^ah   Wood, W ^ah   Rossbach, J ^ai   Bijnens, L ^aj   van de Velde, C ^aj   Cunningham, M P ^ak   Bastert, G ^al   Rauschecker, H ^al   Sauer, R ^al   Sauerbrei, W ^al   Schauer, A ^al   Schumacher, M ^al   de Schryver, A ^am   Belfiglio, M ^an   Mari, E ^an   Nicolucci, A ^an   Scorpiglione, N ^an   Yosef, H M A ^ao   McArdle, C S ^ap   Smith, D C ^ap   Lara, P C ^aq   Boccardo, F ^ar   Rubagotti, A ^ar   Erazo, A ^as   Medina, J Y ^as   Izuo, M ^at   Morishita, Y ^at   Bentley, A ^au   Doran, Z ^au   Fentiman, I S ^au   Hayward, J L ^au   Rubens, R D ^au   Kaufmann, M ^av,aw   Jonat, W ^av   von Fournier, D ^aw   Fountzilas, G ^ax   Klefstrom, P ^ay   Blomqvist, C ^az   Cuzick, J ^q   Margreiter, R ^ba   Castiglione, M ^bb,dl   Cavalli, F ^bb   Collins, J ^bb   Forbes, J ^bb   Gelber, R D ^bb   Goldhirsch, A ^bb,dl   Lindtner, J ^bb   Price, K N ^bb   Rudenstam, C M ^bb   Senn, H J ^bb,dl   Bliss, J M ^bc   Coombes, R C ^bc   Marty, M ^bc   Borovik, R ^bd   Brufman, G ^bd   Hayat, H ^bd   Robinson, E ^bd   Wigler, N ^bd   Pannuti, F ^be   Takashima, S ^bf   Yasutomi, T ^bf   Sonoo, H ^bg   Yamashita, J ^bh   Ogawa, M ^bh   Hupperets, P S G J ^bj   Bonte, J ^bk   Tengrup, I ^bl   Tennvall Nittby, L ^bl   Martin, P ^bm   Romain, S ^bm   Ahmann, D ^bn   Schaid, D J ^bn   Buzdar, A U ^bo   Smith, T ^bo   Hakes, T ^bp   Norton, L ^bp   Wittes, R ^bp   de la Huerta, R ^bq   Sainz, M G ^bq   Bonadonna, G ^br   del Vecchio, M ^br   Valagussa, P ^br   Veronesi, U ^br   Dubois, J B ^bs   Bianco, A R ^bt   Lippman, M E ^bu   Pierce, L J ^bu   Simon, R ^bu   Steinberg, S M ^bu   Myles, J D ^bv   Pater, J L ^bv   Pritchard, K I ^bv,do,dp   Anderson, S ^bw   Brown, A ^bw   Bryant, J ^bw   Costantino, J ^bw   Dignam, J ^bw   Fisher, B ^bw   Redmond, C ^bw   Wieand, S ^bw   Wolmark, N ^bw   Jackson, I M ^bx   Palmer, M K ^bx   Ingle, J N ^by   Suman, V J ^by   Bengtsson, N O ^bz   Larsson, L G ^bz   Lythgoe, J P ^ca   Kissin, M ^cb   Hannisdal, E ^cc   Varhaug, J E ^cc   Nissen Meyer, R ^cd,dd   Blamey, R W ^ce   Mitchell, A K ^ce   Robertson, J F R ^ce   Nakamura, Y ^cf   Mathe G ^cg   Misset, J L ^cg   Abu Zahra, H T ^ch   Clarke, E A ^ch   McLaughlin, J R ^ch   Clark, R M ^ci   Levine, M ^ci   Morimoto, K ^cj   Sawa, K ^ck   Takatsuka, Y ^ck   Gundersen, S ^cd   Hauer Jensen, M ^cd   Host, H ^cd,db   Crossley, E ^cl   Harris, A ^cl   Baker, C ^cm   Beighton, A ^cm   Clarke, M ^cm   Collins, R ^cm   Davies, C ^cm   Elphinstone, T ^cm   Evans, V ^cm   Godwin, J ^cm   Greaves, E ^cm   Harwood, C ^cm   Headon, A ^cm   Hicks, C ^cm   Jackson, D ^cm   James, S ^cm   Lau, E ^cm   McGale, P ^cm   Mead, G ^cm   Monaghan, H ^cm   Mozley, S ^cm   Naughten, A ^cm   Peto, R ^cm   Tooth, A ^cm   Wheatley, K ^cm   Rambert, P ^cn   Asselain, B ^co   Salmon, R J ^co   Vilcoq, J R ^co   Arriagada, R ^cp   Hill, C ^cp   Laplanche, A ^cp   Le M G ^cp   Spielmann, M ^cp   Cocconi, G ^cq   di Blasio, B ^cq   Catalano, R ^cr   Creech, R H ^cr   Brockschmidt, J ^cs   Cooper, M R ^cs   Andrysek, O ^ct   Barkmanova, J ^ct   Falkson, C I ^cu   Abraham, M ^cv   Klijn, J G M ^cw   Treurniet Donker, A D ^cw   van Putten, W L J ^cw   Easton, D ^cx   Powles, T J ^cx   Gazet, J C ^cy   Semiglazov, V ^cz   Businico, A ^da   Sardinia, S ^da   Deshpande, N ^da   di Martino, L ^da   Douglas, P ^db   Lindtner, A ^db   Notter, G ^db   Bryant, A J S ^dc   Ewing, G H ^dc   Krushen Kosloski, J L ^dc   Forrest, A P M ^de   Jack, W ^de   McDonald, C ^de   Moller T R ^df   Ryden S ^df   Carstensen, J ^dg   Hatschek, T ^dg   Soderberg M ^dg   Carpenter, J T ^dh   Albain, K ^di   Crowley, J ^di   Green, S ^di   Martino, S ^di   Osborne, C K ^di   Ravdin, P M ^di   Rutqvist, L E ^dj   Wallgren, A ^dj   Holm, L E ^dk   Thurlimann B ^dl   Brenner, H ^dm   Hercbergs, A ^dm   Yoshimoto, M ^dn   DeBoer, G ^do   Paterson, A H G ^do   Meakin, J W ^dp   Panzarella, T ^dp   Naja, A ^dq   Bahi, J ^dr   Reid, M ^ds   Spittle, M ^ds   Senanayake, F ^dt   Love, R R ^du   de Mets, D L ^du   Bergh, J ^dv   Holmberg, L ^dv   Sevelda, P ^dw   Zielinsky, C C ^dw   Gnant, M ^dw   Jakesz, R ^dw   Buchanan, R B ^dx   Royle, G T ^dx   Dunn, J A ^dy   Gillespie, W M ^dy   Kelly, K ^dy   Morrison, J M ^dy   Litton, A ^dz   Chlebowski, R T ^ea   Bezwoda, W R ^eb   Caffier, H ^ec   more..

^a ACETBC   (Japan)

^b Integraal Kankercentrum   (Netherlands)

^c METAXA CANCER HOSPITAL   (Greece)

^d Auckland Breast Cancer Study Group   (New Zealand)

^e Australian New Zealand Breast Cancer Trials Group   (Australia)

^f Belgian Adjuvant Breast Cancer Project   (Belgium)

^g Berlin Brandenburgische Akademie der Wissenschaften   (Germany)

^h Birmingham General Hospital   (United Kingdom)

ⁱ INSTITUT BERGONIÉ   (France)

^j JULES BORDET INSTITUTE   (Belgium)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l BRADFORD ROYAL INFIRMARY   (United Kingdom)

^m BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁿ Caen Centre Regional Francois Baclesse   (France)

^o ADDENBROOKE S HOSPITAL   (United Kingdom)

^p Cancer and LeGBRemia Group B   (United States)

^q IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^r UNIVERSITY OF CAPE TOWN   (South Africa)

^s Cardiff Surgery Trialists   (United Kingdom)

^t CASE WESTERN RESERVE UNIVERSITY   (United States)

^u Central Oncology Group   (United States)

^v CENTRE LÉON BÉRARD   (France)

^w CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^x UNIVERSITY OF CHICAGO   (United States)

^y CHRISTIE HOSPITAL   (United Kingdom)

^z Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^aa Danish Cancer Registry   (Denmark)

^ab Back Center of Copenhagen   (Denmark)

^ac Cracow Institute of Oncology   (Poland)

^ad CRCRAMS   (Russian Federation)

^ae Danish Breast Cancer Cooperative Group   (Denmark)

^af Dublin St LGBRe's Hospital   (Ireland)

^ag HEINRICH HEINE UNIVERSITY   (Germany)

^ah Eastern Cooperative Oncology Group   (United States)

^ai Diakonie Klinikum Hamburg   (Germany)

^aj European Organisation of Research and Treatment of Cancer   (Belgium)

^ak EVANSTON HOSPITAL   (United States)

^al GBSG   (Germany)

^am GHENT UNIVERSITY HOSPITAL   (Belgium)

^an GIVIO Interdisciplinary Group for Cancer Care Evaluation   (Italy)

^ao BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^ap VICTORIA INFIRMARY   (United Kingdom)

^aq UNIVERSITY OF GRANADA   (Spain)

^ar Gruppo Ricerca Ormono Chemio Terapia Adiuvante (GROCTA)   (Italy)

^as Guadalajara Hospital de 20 Noviembre   (Mexico)

^at GUNMA UNIVERSITY   (Japan)

^au GUY S HOSPITAL   (United Kingdom)

^av Gynecological Adjuvant Breast Group (GABG)   (Germany)

^aw UNIVERSITY OF HEIDELBERG   (Germany)

^ax Hellenic Cooperative Oncology Group   (Greece)

^ay Helsinki Deaconess Medical Centre   (Finland)

^az UNIVERSITY OF HELSINKI   (Finland)

^ba UNIVERSITY OF INNSBRUCK   (Austria)

^bb International Breast Cancer Study Group (Ludwig)   (Switzerland)

^bc INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^bd Israel NSABC   (Israel)

^be Italian Cooperative Chemo Radio Surgical Group   (Italy)

^bf Japanese National Hospitals Group Breast Cancer Study Group   (Japan)

^bg KAWASAKI MEDICAL SCHOOL   (Japan)

^bh KUMAMOTO UNIVERSITY   (Japan)

^bi Kyushu National Cancer Center   (Japan)

^bj Breast Cancer Study Group of the Comprehensive Cancer Centre   (Netherlands)

^bk Louvain Academisch Ziekenhuis St Rafael   (Belgium)

^bl LUND UNIVERSITY   (Sweden)

^bm Marseille Laboratoire de Cancerologie Biologique APM   (France)

^bn MAYO CLINIC   (United States)

^bo UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^bp MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^bq Mexican National Medical Centre   (Mexico)

^br NATIONAL CANCER INSTITUTE   (Italy)

^bs Montpellier Centre Paul Lamarque   (France)

^bt UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^bu NATIONAL CANCER INSTITUTE   (United States)

^bv Queen's Cancer Research Institute   (Canada)

^bw National Adjuvant Breast and Bowel Project   (United States)

^bx Nolvadex Adjuvant Trial Organisation   (United Kingdom)

^by North Central Cancer Treatment Group Rochester   (United States)

^bz North Sweden Breast Cancer Group   (Sweden)

^ca North Western British Surgeons   (United Kingdom)

^cb NORTHWICK PARK HOSPITAL   (United Kingdom)

^cc Norwegian Breast Cancer Group   (Norway)

^cd OSLO UNIVERSITY HOSPITAL   (Norway)

^ce NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^cf OITA PREFECTURAL HOSPITAL   (Japan)

^cg Oncofrance   (France)

^ch Ontario Cancer Treatm Res Found   (Canada)

^ci PEDIATRIC ONCOLOGY GROUP OF ONTARIO   (Canada)

^cj Osaka Prefecture University   (Japan)

^ck OSAKA NATIONAL HOSPITAL   (Japan)

^cl CHURCHILL HOSPITAL   (United Kingdom)

^cm CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^cn CENTRE RENÉ HUGUENIN   (France)

^co INSTITUT CURIE   (France)

^cp INSTITUT GUSTAVE ROUSSY   (France)

^cq Parma Hospital   (Italy)

^cr Philadelphia Fox Chase Cancer Centre   (United States)

^cs Piedmont Oncology Association   (United States)

^ct CHARLES UNIVERSITY   (Czech Republic)

^cu UNIVERSITY OF PRETORIA   (South Africa)

^cv Italia 1586 PB A   (Argentina)

^cw ERASMUS MEDICAL CENTER   (Netherlands)

^cx ROYAL MARSDEN HOSPITAL   (United Kingdom)

^cy ST GEORGE S HOSPITAL   (United Kingdom)

^cz N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^da Sardinia Oncology Hospital   (Italy)

^db SASIB International Trialists   (South Africa)

^dc SASKATCHEWAN CANCER AGENCY   (Canada)

^dd Scandinavian Adjuvant Chemotherapy Study Group   (Norway)

^de Scottish Cancer Trials Office   (United Kingdom)

^df South Swedish Breast Cancer Group   (Sweden)

^dg South East Sweden Breast Cancer Group   (Sweden)

^dh Southeastern Cancer Study Group and Alabama Breast Cancer Project   (United States)

^di Southwest Oncology Group   (United States)

^dj Stockholm Breast Cancer Study Group   (Sweden)

^dk KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^dl SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^dm TEL AVIV UNIVERSITY   (Israel)

^dn CANCER INSTITUTE HOSPITAL   (Japan)

^do Toronto Edmonton Breast Cancer Study Group   (Canada)

^dp PRINCESS MARGARET HOSPITAL   (Canada)

^dq INSTITUT CLAUDIUS REGAUD   (France)

^dr SALAH AZAIEZ INSTITUTE   (Tunisia)

^ds GBR Multicentre Cancer Chemotherapy Study Group   (United Kingdom)

^dt GBR/Asia Collaborative Breast Cancer Group   (United Kingdom)

^du UNIVERSITY OF WISCONSIN MADISON   (United States)

^dv Cancer Center Uppsala Örebro   (Sweden)

^dw UNIVERSITY OF VIENNA   (Austria)

^dx Wessex Radiotherapy Centre   (United Kingdom)

^dy West Midlands Oncology Association   (United Kingdom)

^dz West of Scotland Breast Trial Group   (United Kingdom)

^ea Western Cancer Study Group   (United States)

^eb UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^ec UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; EARLY CANCER; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032537396     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11423-4     Document Type: Article

References (26)

1. 1 Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. N Engl J Med 1988; 319:1681-92.
2. 2 Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer, vol 1: worldwide evidence 1985-1990. Oxford: Oxford University Press, 1990.
3. 3 Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15: 71-85.
4. 4 Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomised trials. N Engl J Med 1995; 333: 1444-55.
5. 5 Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-96.
6. 6 Knight WA, Osborne CK, McGuire WL. Hormonal receptors in primary and advanced breast cancer. Clin Endocrinol Metab 1980; 9: 361-68.
7. 7 Elwood JM, Godolphin W. Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer 1980; 42: 635-44.
8. 8 Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J (eds). Cancer incidence in five continents, vol VI. Lyon: International Agency for Research on Cancer, 1992.
9. 9 Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking T, for the Stockholm Breast Cancer Study Group. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87: 645-51.
10. 10 International Agency for Research on Cancer. IARC monograph on the evaluation of carcinogenic risks to humans: some pharmaceutical drugs. 1996; 66: 253-365.
11. 11 Rutqvist LE, Cedermark B, Glas U, et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials. Int J Radiation Oncol Biol Phys 1989; 16: 629-39.
12. 12 McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ 1995; 311: 977-80.
13. 13 Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37.
14. 14 Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860-64.
15. 15 Gotto AM. Results of recent large cholesterol-lowering trials and implications for clinical management. Am J Cardiol 1997; 79: 1663-66.
16. 16 Williams GM, Iatropoulos MJ, Djordjevic MV, et al. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 14: 315-17.
17. 17 Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from smoking in developed countries 1950-2000: indirect estimates from national vital statistics. Oxford: Oxford University Press, 1994.
18. 18 Clark GM, Harvey JM, Osborne CK, Allred DC. Estrogen receptor status determined by immuno-histochemistry is superior to biochemical ligand-binding assay for evaluating breast cancer patients. Proc ASCO 1997; 16: 454 (abstr).
19. 19 Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88: 1543-49.
20. 20 Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996; 88: 1834-39.
21. 21 Delozier T, Spielmann M, Macé-Lesec'h J et al. Short-term versus lifelong adjuvant tamoxifen in early breast cancer (EBC): a randomized trial (TAM-01). Proc ASCO 1997; 16: 1289 (abstr).
22. 22 Peto R. Five years of tamoxifen - or more? J Natl Cancer Inst 1996; 88: 1791-93.
23. 23 Fisher B, Dignam J, Bryant J, et al. The worth of five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529-42.
24. 24 Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: the Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74: 297-99.
25. 25 Tormey DC, Gray R, Falkson HC (for the Eastern Cooperative Oncology Group). Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996; 88: 1828-33.
26. 26 Cuzick J. Chemoprevention of breast cancer with tamoxifen. In: Hakama M, Beral V, Buiatti E, Faivre J, Parkin DM, eds. Chemoprevention in cancer control. IARC Scientific publication no 136. Lyon: IARC, 1996: 95-109.